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Abstract
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder resulting from polyglutamine expansion
in the huntingtin (HTT) protein and for which there is no cure. Although suppression of both wild type and mutant HTT
expression by RNA interference is a promising therapeutic strategy, a selective silencing of mutant HTT represents the safest
approach preserving WT HTT expression and functions. We developed small hairpin RNAs (shRNAs) targeting single
nucleotide polymorphisms (SNP) present in the HTT gene to selectively target the disease HTT isoform. Most of these
shRNAs silenced, efficiently and selectively, mutant HTT in vitro. Lentiviral-mediated infection with the shRNAs led to
selective degradation of mutant HTT mRNA and prevented the apparition of neuropathology in HD rat’s striatum expressing
mutant HTT containing the various SNPs. In transgenic BACHD mice, the mutant HTT allele was also silenced by this
approach, further demonstrating the potential for allele-specific silencing. Finally, the allele-specific silencing of mutant HTT
in human embryonic stem cells was accompanied by functional recovery of the vesicular transport of BDNF along
microtubules. These findings provide evidence of the therapeutic potential of allele-specific RNA interference for HD.
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Introduction
HD is an autosomal dominant neurodegenerative disease that
affects 1 in 10,000 adults [1]. The symptoms, which include
progressive motor, psychiatric and cognitive dysfunctions, are
associated with the degeneration of the major population of striatal
neurons, the GABAergic spiny projection neurons. The mutation
underlying HD is an expansion of a trinucleotide CAG repeat
which encodes a polyglutamine (polyQ) tract in the N-terminal
region of the HTT protein [2]. This mutation confers a new toxic
function on the protein, in part through the production of short N-
terminal fragments carrying the polyglutamine and the accumu-
lation of misfolded HTT [3].
Gene silencing techniques, aiming to reduce intracellular levels
of polyglutamine-encoding mRNA, have the potential to halt, or
at least delay, the process of neuronal death at its source and are
therefore promising for the treatment of polyglutamine (polyQ)
diseases [4]. However, most in vivo studies have been performed
with small interfering RNAs (siRNAs) that do not discriminate
between the WT and mutant alleles. Several groups including ours
demonstrated that non allele-specific silencing of HTT with shRNA
is well tolerated up to 9 months in a lentiviral-based HD model [5]
and in transgenic N171-82Q mice [6] but leads to transcriptomic
changes; the functional consequences of these changes are
currently unknown. Thus, an allele-specific silencing of mutant
HTT is potentially the optimal solution for blocking polyQ
pathogenesis.
Recently, strategies based on chemically modified single-
stranded RNAs targeting the CAG expansion were developed to
selectively target mutant HTT [7–9]. As an alternative strategy,
single nucleotide polymorphisms (SNP) have been used to
discriminate between WT and mutant transcripts associated with
polyglutamine disorders [10–12]. Studies with HD patients
indicate that the level of heterozygosity of a limited number of
SNP is sufficient to select most HD patients, confirming the
feasibility of the approach [13–15]. Two studies showed that
targeting three SNP would be sufficient to treat 75% of their
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respective HD cohort [13]. Note that a large proportion of patients
of European origin clusters in a single haplotype with a specific set
of SNPs [16–18].
One challenge is that available HD animal models are not
entirely appropriate for assessing the therapeutic efficacy and
selectivity of shRNAs targeting SNPs. Knock-in mice do not
express the human HTT gene [19] and transgenic models
expressing short N-terminal fragments of human HTT (R6/2,
N171-82Q) or viral-based HD models do not contain the
corresponding SNPs [20,21]. Transgenic mice expressing full-
length HTT possess only one human allele [22,23], allowing
analysis of efficacy but not selectivity, which is an important aspect
of this strategy. Only lately, one fully humanized transgenic mouse
model of HD was created, containing two human HTT alleles, but
it was not available at the time we started the study [24].
Therefore, we developed new HD models based on lentiviral
expression of a chimeric mutant HTT reporter system. Using these
new tools and neural derivatives of HD human embryonic stem
cells (hESCs), we tested the efficacy and selectivity of shRNAs
targeting SNPs in exons 39, 50, 60 and 67 of the human HTT
gene and functional recovery associated with this silencing.
Materials and Methods
Plasmids and lentiviral vector production
We selected four SNPs within the HTT gene: rs363125 (exon
39, A or C), rs362331 (exon 50, C or T), rs2276881 (exon 60, A or
G) and rs362307 (exon 67 C or T). We designed eight small-
hairpin RNA (shRNA) targeting these HTT isoforms and cloned
them in lentiviral vectors (Materials and Methods S1, Table S1).
To assess the efficacy and the selectivity of these shRNAs, we
produced constructs encoding chimeric mutant HTT, consisting of
the sequence of the first 171 amino acids of the human HTT with
82 CAG repeats and fused to a part of HTT exons containing the
SNP (SIN-W-PGK-htt171-82Q-exon; Materials and Methods S1,
Table S2). Each chimeric mutant HTT construct contains one
SNP of interest.
Lentiviral vectors encoding the various shRNAs and the eight
chimeric HTT were produced in 293T cells using a 4-plasmid
system as previously described [25]. The particle content of viral
batches was determined by p24 antigen ELISA (RETROtek,
Gentaur, France). The stocks were stored at 280uC until use.
In vivo experimental design and animals
Two sets of in vivo experiments were carried out. First, we
validated the chimeric targets and tested shRNAs in 200 g adult
male Wistar rats (Iffa Credo/Charles River, Les Oncins, France).
Second, BACHD mice expressing full-length mutant HTT with
97Q [23] were used to validate the shRNA therapeutic strategy.
BACHD mice were genotyped to identify HTT isoform present at
SNPs studied. Stereotaxic injections of the lentiviral vectors are
described in the Materials and Methods S1.
The animals were housed in a temperature-controlled room and
maintained on a 12 h day/night cycle. Food and water were
available ad libitum. All experiments were carried out in accordance
with the European Community directive (86/609/EEC) for the
care and use of laboratory animals as well as the Swiss animal
welfare laws under the authorization nu VD 2486 and 2487 from
the Service de la consommation et des affaires ve´te´rinaires du
Canton de Vaud, Switzerland.
Laser Capture Microdissection and punches
Four weeks after co-infection of chimeric HTT construct with
fully matched or mismatched shRNA, or shCtrl, the animals were
sacrificed by administration of an overdose of sodium pentobar-
bital. Processing of the brains for laser capture microdissection and
RT-qPCR were conducted as previously described with human
specific primers [5] (platform profileXpert: www.profilexpert.fr).
BACHD mice injected with matched shRNA and shCtrl were
sacrificed. One millimeter-thick fresh brain slices were obtained
using a mouse brain matrix and punches were sampled from the
GFP-positive area under a fluorescent microscope and were
quickly lyzed in Trizol and stored at 280uC until RNA extraction.
Quantitative real-time PCR from 293T cells or BACHD
striata
Total RNA was extracted with Trizol reagent 48 hrs post-
transfection of 293T cells or 4 weeks post-injection of BACHD
mice. RT-qPCR was performed in triplicate with random-primed
(Invitrogen, Cergy Pontoise, France) cDNAs generated from 0.3-
1 mg total RNA. Quantitative PCR was carried out in a 20 ml
reaction volume containing Platinum SYBR Green qPCR super
Mix-UDG (Invitrogen Cergy Pontoise, France), and 10 mM of
both forward and reverse primers recognizing a sequence of
human HTT present in the first part of all chimeric constructs and
in the BACHD human allele (sequences in Table S3) using a
Realplex thermal cycler (Eppendorf). Three to 5 samples from
cells and 4–10 samples from the striatum punches were subjected
to RT-qPCR analyses. Values for HTT mRNA were normalized
to a reference: b-actin (ACTB) or peptidyl propyl isomerase A
(PPIA) and are expressed as mean percentages 6 SEM relative to
the control condition.
Histological processing
Four to 8 weeks post-lentiviral injection, the animals were given
an overdose of sodium pentobarbital and were transcardially
perfused with a phosphate solution followed by 4% paraformal-
dehyde (PFA, Sigma-Aldrich, St. Louis, Missouri, United States)
and 10% picric acid for fixation. The brains were processed as
previously described [5] for immunohistochemistry for dopamine
and cAMP-regulated phosphoprotein of a molecular mass of
32 kDa (DARPP-32), ubiquitin (Ubi) and mutant HTT (EM-48).
Pictures were taken using 4x, 20x or 63x objectives on an Olympus
AX70 microscope.
Quantification of DARPP-32 lesions and formation of
inclusions
The loss of DARPP-32 expression was analyzed by collecting
digitized images of twelve sections per animal (separated by
300 mm) with an optic bench and by quantifying the lesion areas in
mm2 with image analysis software (MCID Core 7.0, InterFocus
Imaging, GE Healthcare Niagara Inc.). Lesion areas in each
section were determined as regions poor in DARPP-32 staining
relative to the surrounding tissue. The lesion volume for each
animal is expressed in mm3, calculated as the sum of the total
lesion area in mm2 of all sections multiplied by the inter-section
distance (300 mm). For estimation of the number of ubiquitin-
positive HTT inclusions, 12 serial coronal sections of the striatum
(separated by 300 mm) were scanned with a 10x objective using a
Zeiss Axioplan2 imaging microscope equipped with an automated
motorized stage and acquisition system (Mercator Pro V6.50,
ExploraNova). All ubiquitin-positive objects with an apparent
cross-sectional area comprised between 1 and 50 mm2 were
measured as previously reported [5]. The same parameters were
applied for EM-48 aggregates quantification. Bravais-Pearson
correlation was performed to validate the use of Ubiquitin staining
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as a measure of HTT aggregation (Statistica, Statsoft, Maisons-
Alfort, France).
Neural Stem Cells culture and nucleofection
Neural stem cells (NSCs) were obtained and maintained as
described previously [26]. NSC lines were differentiated from the
following human ES lines: SA-01 (WT XY, passages 30-83,
Cellartis AB, Sweden), H9 (WT XX, passages 40–60, WiCell
Research Institute), VUB05 (HD XY, 44 CAG, passages 35–130,
AZ-VUB, Belgium [27]), SIVF017 (HD, XY, 40 CAG, passag-
es18–35, Sydney IVF Stem Cells, Australia [28]), SIVF018 (HD
XX, 46 CAG, passage 18–30, Sydney IVF Stem Cells, Australia
[28]) and Huez2.3 (HD XX, 44 CAG, passages 25–47, IGBMC,
Strasbourg [29]).
Genotypes for SNP rs362331 of Huez2.3, VUB05 and SIVF018
NSC lines were analyzed by sequencing the PCR product
encompassing this SNP generated using the following primers:
59-CCCAAACGAAGGTACACGA and 59-CCTGTTGGCC-
ATCTCTCACC.
For videomicroscopy analysis, NSCs were electroporated with
1 mg BDNF-mCherry, a gift from G. Banker (Oregon Health and
Science University) and 4 mg SIN-CWP-GFP-TRE-H1-shCtrl
(controls: shLUC or shUNIV), -sh50T or -sh50C (see Table S2).
NSCs were plated on glass coverslips previously coated with Poly-
L-orninthine and Laminin (Sigma, St. Louis, Missouri, United
States). Live videomicroscopy was carried out seven to ten days
after transfection using an imaging system as previously described
[30] with little modifications (Materials and Methods S1). After
videomicroscopy experiments, the neuronal cultures were pro-
cessed for immunofluorescence for anti-HTT-2166 (Materials and
Methods S1).
Results
Development of SNP-specific shRNA for the treatment of
HD
To distinguish the normal and disease HTT alleles in HD
patients, we developed shRNAs targeting the disease isoform of
heterozygous single-nucleotide polymorphisms (SNP). We pro-
duced eight shRNAs corresponding to four SNP present within the
HTT gene: in exons 39, 50, 60 and 67 (Fig. 1A). The selection was
based on their presence in HTT exons and a high frequency of
heterozygosity in the human population (http://www.ncbi.nlm.
nih.gov/snp and [13,14,16]). DNAs encoding the shRNAs
targeting each SNP (shSNPs: sh39A, sh39C, sh50C, sh50T,
sh60A, sh60G and sh67C, sh67T) were inserted into a lentiviral
vector [5] (Fig. 1B). The SNP was localized at 10 (p10, exons 39,
60 and 67) or 11 (p11, exon 50) bases from the 59 end of the guide
strand of the shRNA to ensure selective cleavage of the target
sequence [31]. All the exons selected correspond to the 39 part of
the HTT mRNA. As the transcript (.10 kb) is too long for the
entire sequence to be inserted into lentiviral vectors, we created a
chimeric HTT gene to test the efficacy and selectivity of our
shSNPs. The chimeric HTT contains a N-terminal fragment of
mutant HTT corresponding to the first 171 amino acids with 82
glutamines (Htt171-82Q) fused in frame to the part of the protein
encoded by the exons carrying the SNP of interest (Fig. 1A and
Materials and Methods S1). A sequence encoding the HA tag was
added to 39 the end to facilitate detection of the resulting fusion
proteins.
We tested the ability of the lentiviral vectors encoding the
shSNPs to silence their corresponding chimeric constructs. 293T
cells were co-transfected with the plasmids expressing the chimeric
HTT and the shRNA, and mutant HTT levels were analyzed by
quantitative RT-PCR (Fig. 2a) and western blotting (Fig. 2B).
The presence of fully matched shSNP was associated with robust
degradation of the chimeric HTT mRNA (Fig. 2A), with the
shSNP targeting exons 39 and 67 being the most potent (around
80% of degradation of the targeted mRNA). In contrast, HTT
mRNA levels were only modestly reduced (10% of silencing in
most cases) following co-transfection with mismatched shSNP
(Fig. 2A). This demonstrates the capacity of this approach to
discriminate between the two HTT alleles. Selectivity was however
poorer for sh50T and sh67C/T, with 40–50% degradation of
HTT mRNA with the mismatched shRNAs. Additional experi-
ments (n = 3) were performed to demonstrate the correlation
between the HTT mRNA and protein levels (Figure S1). HTT
protein levels were decreased in all matched and, to a lower extent,
in most mismatched conditions. A strong correlation was observed
between the HTT mRNA and protein levels, in agreement with
published studies [32,33].
Effective allele-specific silencing of mutant HTT in the HD
rat model
To evaluate the therapeutic efficacy of this approach in vivo, we
needed an appropriate model expressing the SNPs of interest. We
injected the various chimeric Htt171-82Q-exon vectors and the
pathogenic control Htt171-82Q vector into the striatum of adult
rats to induce a local expression of the disease protein, and
compared the severity of HD neuropathology. Misfolded HTT
labeled with the ubiquitin antibody was detected and the typical
lesion with a down-regulation of DARPP-32 expression was
observed for all the chimeric constructs (Fig. 3A), consistent with
previous findings [34]. This ubiquitin staining is faithfully
reflecting the accumulation of misfolded HTT protein revealed
with the EM48 antibody (Figure S2). After 8 weeks, there was no
apparent difference between animals injected with the Htt171-
82Q or the other Htt171-82Q-exon vectors (Fig. 3A).
To assess the efficacy of allele-specific silencing, we co-injected
lentiviral vectors encoding human Htt171-82Q-exon with the
corresponding shSNP into the striatum of adult rats. Four weeks
post-injection, using the GFP-reporter gene present on the vectors
expressing the shSNP to identify the infected cells (mostly neurons
as previously reported [35] [36]), the GFP-positive area was laser
microdissected and the amount of HTT mRNA was determined
by RT-qPCR. All shSNPs efficiently silenced HTT gene expres-
sion (Fig. 3B). In the same experiment, we then tested the ability
of the shRNAs to selectively discriminate SNPs in vivo. The
striatum of adult rats was co-injected with Htt171-82Q-exon and
the corresponding mismatched shRNAs. The shSNPs targeting
exons 50 or 60 efficiently discriminated between the two SNP
variants (0 to less than 35% degradation of mismatched HTT
mRNA), whereas the shSNPs targeting exon 39 or 67 did not
discriminate (around 80% of degradation) (Fig. 3B). These
experiments demonstrate the efficiency of all shSNPs is accompa-
nied by good specificity for five of the eight shSNPs.
Inhibition of HD neuropathology in matched shSNP-
treated lentiviral HD rat model
To further confirm the therapeutic potential of the shSNPs, we
investigated the formation of HTT aggregates and striatal
neuronal dysfunction. HTT inclusions are a hallmark of the
pathology and a reliable marker of the severity of HD pathology.
We co-injected the chimeric constructs with either the fully
matched or mismatched shSNPs or a shRNA control (shCtrl).
Eight weeks later, we quantified the down-regulation of DARPP-
32 expression and the number of ubiquitin-positive aggregates.
Allele-Specific Silencing in Huntington’s Disease
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e99341
DARPP-32 immunostaining (Fig. 4A) showed that the lesion size
was reduced in the matched conditions, except for the sh39, but
not in control and some mismatch injected areas (Fig. 4C). This
staining indicated that most of the shSNPs in the matched
condition inhibited the appearance of an HD neuropathology with
very high efficacy. Large numbers of ubiquitin immunostained
aggregates were observed in the control and most mismatch
injected areas, whereas smaller numbers were found in the
matched conditions (Figs. 4B and 4D). In the mismatch
condition, the SNP discrimination power of sh39 and sh67 was
low (not significant; Figs. 4C and 4D). Injection of the shSNP
only didn’t lead to striatal dysfunction based on DARPP32
staining, 8 weeks after injection (data not shown).
Pfister and collaborators have shown that for the SNP in exon
39, placing the mismatch at position 16 rather than 10 improved
the discrimination ratio in a luciferase reporter system [13]. We
therefore developed new vectors encoding sh39p16 and compared
them with the sh39p10 constructs by evaluating in vitro mutant
HTT mRNA levels in 293T cells co-transfected with the chimeric
HTT and the shRNA (Figure S3A) and in vivo lesion volumes and
the numbers of ubiquitin-positive aggregates in co-injected rats
(Figure S3B and S3C). Sh39p16 efficiently silenced mutant HTT,
however the selectivity was not improved by placing the
mismatched base at position 16 of the shRNA.
Efficient silencing of mutant HTT in BACHD mice using
matched shSNP
BACHD mice express full-length human mutant HTT at
physiological levels. Human mutant HTT mRNA in these mice is
approximately 1.36 fold the level of endogenous WT HTT [37];
whereas mutant HTT mRNA level in animals injected with
lentiviral vectors is about 25 times higher than the endogenous one
[5]. We therefore used these animals to measure silencing efficacy
on endogenous full-length HTT mRNA in the disease context.
Genotyping showed that these mice express exon39C, exon60G
and exon67C, and exon50T in agreement with Carroll et al. [15].
The four matched shSNPs and the shCtrl were injected bilaterally
into the striatum of these adult and pre-symptomatic transgenic
mice (we chose to inject sh39Cp16 because it is more efficacious
than sh39Cp10, Figure S3). Four weeks post-injection, the mice
were sacrificed and the GFP-positive area of the striatum was
grossly punched out from 1 mm-thick striatal slices. HTT mRNA
was measured by RT-qPCR from these punches to measure the
average silencing obtained in the striatum (i.e. infected/treated
and non-infected cells) and evaluate treatment efficiency, which
can be expected with this gene transfer approach. The data
gathered from this in vivo experiment and those presented in
Figures 3–4 are therefore complementary and provide two distinct
types of information on the allele-specific silencing. In striatal
punches from BACHD mice, the amounts of mutant HTT mRNA
(Fig. 5A) were lower (around 50%) in mice treated with each of
the four shSNPs than shCtrl. There was no significant difference in
the mRNA levels of the neuronal marker Neuronal Nuclei (NeuN)
between any of the samples (Fig. 5B) confirming that they were
comparable. To further demonstrate the selectivity of the silencing
on full-length human mutant HTT, we performed one additional
experiment in BACHD mice injected with sh50T, sh50C and
shCtrl. As expected, a statistically significant silencing was
observed with the sh50T while HTT mRNA level in the sh50C
group was similar to the control group (Fig. 5C). Therefore, the
capacity to discriminate the two alleles was confirmed.
Functional recovery after allele-specific silencing of
mutant HTT in neurons derived from HD-hESCs
To assess the silencing of endogenous HTT and the functional
recovery, we took advantage of the recent isolation of human
Figure 1. Schematic representation of the chimeric HTT- and shSNP-containing lentiviral vectors. (A) We chose four SNP within the
human HTT transcript: exon 39 (rs363125), exon 50 (rs362331), exon 60 (rs2276881) and exon 67 (rs362307). This last SNP is located after the stop
codon, in the 39UTR of the HTT gene. The chimeric HTT with the exon 39 SNP is illustrated as an example: the sequence surrounding the SNP (A or C)
is fused in frame to the 59 sequence of mutant HTT encoding the first 171 amino acids with 82Q. A sequence encoding the HA tag is added at 39 the
end of all fusion proteins to facilitate detection. The fusion construct is then inserted into a SIN transfer vector. (B) Representation of a lentiviral vector
expressing the shSNP (example of sh39C). The sequence corresponding to the shRNA is inserted downstream from a tetracycline responsive element
(TRE) and a H1 promoter in the 39LTR of the vector. A second expression cassette contains a GFP reporter gene under the control of a PGK promoter.
The SNP was located at position 10 or 16 for this particular shSNP, counting from the 59 end of the guide strand of the shRNA.
doi:10.1371/journal.pone.0099341.g001
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neural stem cells (NSCs) from HD-hESCs [26]. We transfected the
HD-NSC line Huez2.3 homozygous for the SNP in exon 50 (T/T)
and demonstrated that the silencing obtained with si50T was
similar to that with the previously described siHtt6, which targets
both alleles [5]. Transfecting the cells with the mismatched siRNA
(si50C) had little effect on HTT expression, confirming the
selectivity of the approach (Fig. 6A). Because the CAG expansion
is located far from the SNP position, we then developed a new
method based on SNP-specific reverse transcription and amplifi-
cation of CAG repeats by PCR, coupled with size detection on a
chip, to link the SNP and the mutant allele in the heterozygous
HD-hESC. Using this strategy, we found that the mutant CAG
expansion (46 or 44 CAG) was associated with the SNP50T in
SIVF018 and VUB05 cells. Treatment of these cells with si50T
and si50C significantly decreased mutant and WT HTT mRNA
levels, respectively, and as expected the silencing was more
pronounced with siHtt6 (Fig. 6B).
Figure 2. Efficacy and selectivity of the shSNP in vitro. (A) Quantitative real-time PCR analyses showing the silencing of HTT mRNA in
transfected 293T cells co-expressing chimeric HTT and shSNP or the control shRNA. Levels of the chimeric HTT mRNA were normalized to b-Actin and
are reported as mean percentages relative to the control condition (set at 100%) 6 SEM (n= 3–5). One-way analyses of variance (ANOVA) were
performed for each SNP. Newman-Keuls Post-hoc comparison between the shCtrl groups and shSNP groups indicated significant efficacy for sh39A,
sh39C, sh50T, sh67T, sh67C (***P,0.001), sh60G (**P,0.01) and sh60A (*P,0.05) whereas the difference between the control condition and the
sh50C condition was not statistically significant. The mismatched shRNA conditions were not significantly different from the control condition except
for 50T+sh50C (**P,0.01), 67T+sh67C and 67C+sh67T (***P,0.001) and they were all significantly different from the matched shRNA conditions
showing the selectivity of this approach in vitro (sh39A, sh39C, sh67C (***P,0.001), sh60G (**P,0.01), sh50C, sh50T, sh60A and sh67T (*P,0.05). (B)
Representative western blot (n = 3) with anti-HA antibody illustrating production of the chimeric proteins. The efficacy test lanes (matched shRNA: M)
evidence the decrease/absence of the corresponding chimeric proteins, whereas in selectivity lanes (mismatched shRNA: Ms) the mutant HTT is still
present as in the control condition (c).
doi:10.1371/journal.pone.0099341.g002
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We tested whether the allele-specific silencing of mutant HTT
was associated with a functional recovery. We took advantage of
the defect in the vesicular trafficking of the brain-derived
neurotrophic factor, BDNF, previously described in primary
cultures expressing mutant HTT [30]. We measured BDNF
anterograde and retrograde velocity in neurons derived from WT
(lines H9 and SA-01) and HD lines (Huez2.3 and SIVF018)
(Fig. 7A). Direct fluorescence allowed us to select cells co-
transfected with BDNF-mCherry and shRNA (GFP) (Fig. 7B).
Kymographs showing the spatial positions of BDNF vesicles
through time were used to quantify the dynamics in different
conditions (Figs. 7C and 7D). When differentiated into neurons,
both HD-lines (Huez2.3 and SIVF018) displayed vesicular
trafficking defects relative to the WT lines (H9 and SA-01)
(Fig. 7A). This confirms that an expansion as limited as 44 CAG is
sufficient to impair transport function [30]. Immunofluorescence
staining confirmed that these cells expressed HTT (Fig. 7B). We
then analyzed mCherry-BDNF transport in the SIVF018 line and
Figure 3. Expression of HTT after co-injection of constructs encoding chimeric mutant HTT and GFP-shSNPs in vivo. (A) Lentiviral
vectors expressing the htt171-82Q fragment or the various chimeric mutant HTT were injected into the striatum of rats (n = 4 per group). Eight weeks
after injection, DARPP-32 and ubiquitin (Ubi) staining (low and high magnification pictures) demonstrated that all the constructs led to HD-like
neuropathology (loss of DARPP-32 staining and ubiquitin-positive aggregates), similar to that with the htt171-82Q lentiviral-based model. (B) Four
weeks after injection, the GFP-positive area was laser-capture microdissected and HTT mRNA was assayed by RT-qPCR. Values for HTT mRNA were
normalized to PPIA and are expressed as mean percentages of the value for the control condition 6 SEM (n= 6). One-way ANOVAs were conducted
for each SNP. 39A: ***P,0.001; 39C: ***P,0.001; 50C: ***P,0.001; 50T: ***P,0.001; 60A: ***P,0.001; 60G: ***P,0.001; 67T: ***P,0.001; 67C: P.
0.05. Newman-Keuls Post-hoc comparison between the shCtrl groups and matched shRNA groups demonstrates significant silencing of all targeted
HTT mRNAs, ***P,0.001, except for exon 67C. Post-hoc comparison between the shCtrl groups and mismatched shRNA groups revealed no
significant differences for sh50T, sh60A or sh60G, a significant difference for sh67C, and highly significant differences for sh39A, sh39C, sh50C and
sh67T. This comparison as the matched/mismatched post-hoc provides evidence of the different selectivities of the shSNPs.
doi:10.1371/journal.pone.0099341.g003
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a second HD heterozygous line, VUB05. Both anterograde and
retrograde trafficking of BDNF was significantly greater in
SIVF018 and VUB05 neurons when the mutant HTT was
silenced with the sh50T, whereas targeting the WT HTT allele
with sh50C had no effect (Figs. 7C and 7D). Thus, allele-specific
silencing of mutant HTT in HD cells is associated with a functional
recovery of BDNF transport. Also, silencing of the mutant allele is
sufficient to alleviate the dominant effect of the mutant HTT over
the WT HTT.
Discussion
Targeting heterozygous SNPs to degrade mutant HTT selec-
tively while preserving the WT transcript is an extremely
promising approach to HD treatment. However, developing and
validating appropriate protocols is challenging. The frequencies
and maps of heterozygous SNPs in the population have been
established [13–18], and the number of SNP candidates is limited
(approximately 40–50) compared to the countless sequences that
could be targeted with a non allele-specific strategy. Also, the
sequences flanking an SNP are not necessarily optimal for shRNA
interaction, and the mismatches in SNPs have different discrim-
ination powers that affect the selectivity of the silencing further
Figure 4. Efficacy and selectivity of the GFP-shSNP in vivo. (A) and (C) DARPP-32 immunostaining and quantification 8 weeks after injection
evidencing loss of this striatal marker in the control and mismatched injected areas but its preservation in the matched conditions, except for sh39
and sh67. The results are expressed as mean volumes in mm3 depleted of DARPP-32 6 SEM (n= 8). One-way ANOVAs were conducted for each SNP:
50C, 50T, 60A, 60G, 67T, and 67C: ***P,0.001. Newman-Keuls Post-hoc comparison between control conditions and test conditions showed a highly
effective prevention of DARPP-32 loss for most of the matched shSNPs and also significant, although less so, prevention of loss for the mismatched
sh50C and sh67. For the other mismatched conditions, the post-hoc test was not significant, indicating the selectivity of the shSNPs. (B) and (D)
Ubiquitin immunostaining (low and high magnification pictures) and quantification showing large numbers of aggregates in the control and
mismatched injected areas and fewer aggregates in the matched conditions. The results are expressed as mean numbers of ubiquitin-positive
aggregates 6 SEM (n= 8). One-way ANOVAs were conducted for each SNP: 39A, 39C, 50C, 50T, 60A, 60G, and 67T: ***P,0.001; 67C: **P,0.01.
Newman-Keuls Post-hoc comparison between control and matched conditions showed highly significant prevention of aggregate formation for all
matched shSNPs. For mismatched conditions, the post-hoc test was not significant except for the mismatched sh39 and sh67.
doi:10.1371/journal.pone.0099341.g004
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reducing the number of possibilities. Furthermore, clinical
implementation will undoubtedly require the development and
validation of several products to treat the most patients.
Here, we addressed some of these issues by targeting four SNP
among the most frequent in the population. We showed that the
eight shRNAs covering these SNPs provide efficient and, in most
cases, selective silencing of HTT in vitro and in vivo and hence are
good candidates for the treatment of many HD patients.
These findings were obtained with novel models developed
specifically for screening shSNPs. The chimeric reporter plasmids
expressing the construct encoding human mutant HTT fused to
the exons containing the various SNP allow large-scale and quick
quantitative analysis of the silencing efficacy and selectivity. We
reported that the allele-specific silencing demonstrated in 293T
cells was reproduced in human NSC derived from HD-hESC lines
involving a mutated HTT corresponding to that responsible for
Figure 5. Effective and selective SNP-specific silencing in BACHD mice. (A) Four weeks after injection of constructs encoding fully matched
shSNP in BACHD mice striatum, the GFP-positive area was dissected and HTT mRNA was assayed by RT-qPCR. Values for HTT mRNA were normalized
to a reference peptidyl propyl isomerase A (PPIA) and are expressed as mean percentages relative to the control condition (set at 100%) 6 SEM
(n = 10). One-way ANOVAs were conducted for each matched SNP for HTT 39C, 50T, 60G, and 67C: ***P,0.001. Newman-Keuls Post-hoc comparison
between the shCtrl and matched shRNA groups demonstrate significant silencing of targeted human HTT mRNA. (B) Samples all showed similar
NeuN gene expression (One-way ANOVAs and Newman-Keuls Post-hoc comparison test). (c) Three weeks after injection of constructs encoding
shCtrl, sh50T and sh50C in BACHD mice striatum, 1 mm3 punches of the GFP infected area were dissected and HTT mRNA was assayed by RT-qPCR
with primers specific for the human HTT. Values for HTT mRNA were normalized to a reference PPIA and are expressed as mean percentages relative
to the control condition (set at 100%) 6 SEM (n= 4–6). One-way ANOVAs were conducted for each groups: *P,0.05. Newman-Keuls Post-hoc
comparison between the shCtrl and the sh50T confirm the silencing of human mutant HTT mRNA, whereas no statistically significant difference was
observed between shCtrl and sh50C groups, demonstrating the selectivity of HTT silencing.
doi:10.1371/journal.pone.0099341.g005
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adult onset HD. These experiments showed that the in vitro
platform based on 293T cells and HD-specific human pluripotent
stem cells is suitable for evaluating the effects of allele-specific
shRNA. We reported that neurons derived from HD-hESCs
reproduce the defect in anterograde and retrograde BDNF
vesicular transport associated with HD [30]. Allele-specific
silencing of mutant HTT restored the mean velocity of BDNF
vesicles to control values. Silencing of WT HTT in neurons
heterozygous for SNP exon 50 did not alter trafficking along
microtubules in neurites, as previously reported [38]. The different
effects of treatment with sh50T and sh50C suggest that these
shSNP are sufficiently potent and selective to modulate axonal
vesicular transport in neurons. Importantly, HTT mRNA levels in
NSC derived from hESC are closer of the values observed in
patient brain samples than in HD-derived fibroblasts or lympho-
blasts (which are 100x lower), increasing the potential value of this
cellular model [26].
Silencing levels were similar to those obtained with shRNA
targeting both alleles [5]. Even though the sequences of these
shSNP were not selected according to established algorithms and
criteria for optimal silencing, all of them efficiently promoted
degradation of the target mRNA. In agreement with Lombardi et
al. [14], we observed that the sh50C/T led to efficient degradation
of the targeted mRNA (74%; fully matched sequence), while a
central mismatch in the shRNA sequence abolished this silencing
(21%; mismatched sequence). In contrast, antisense oligonucleo-
tides (ASO) targeting the exon 50 were associated with poor
discrimination power in human HD fibroblasts [15]. This
discrepancy might be due to differences in the mode of action
between shRNA and ASO, the experimental paradigm, method of
administration modalities or different concentrations.
HD transgenic mice available when we initiated this study,
express only one allele of the human HTT gene and only full-
length HTT genes are suitable for validating the chosen SNP, most
of which map in the 39 part of the gene. We therefore used two
approaches for in vivo validation. As a first screen to assess the
efficacy and selectivity of HTT allele-specific silencing, we injected
lentiviral vectors encoding the first 171 amino acids of the human
mutant HTT fused to the exon containing the SNP into the
striatum of adult rats [5,34]. Our shSNP recognized only the
human HTT transcript, because the targeted regions display only
limited sequence identity with the rodent HTT mRNA. These
experiments therefore replicate allele-specific silencing as it would
occur in human patients. Four weeks after the injection, the
majority of the animals treated with fully matched shRNA showed
HTT mRNA levels that were 80% lower than control values, and
a concomitant reduction of the number of HTT aggregates and
lesion size at 8 weeks. These experiments confirmed the efficacy
Figure 6. Allele specific knock-down of HTTmRNA in human HD NSC. Relative HTT mRNA levels normalized to controls (non-targeting siRNA)
measured by RT-qPCR in HD-NSCs transfected with pan-allelic (siHtt6) or allele-specific HTT-targeting (si50T and si50C) siRNAs. HD-NSCs were derived
from two HD-hESC lines, Huez2.3 (A) and SIVF018 (B), T/T homozygous and C/T heterozygous for SNP rs362331, respectively. n = 4. P-value by one-
way ANOVA and Tukey’s multiple comparison test; *P,0.05; **P,0.01; ***P,0.001; Error bars depict SEM.
doi:10.1371/journal.pone.0099341.g006
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Figure 7. Recovery of BDNF trafficking after allele-specific silencing of mutant HTT in neurons derived from HD-hESCs. (A)
Quantitative analyses of anterograde and retrograde BDNF vesicular velocity in two different WT NSC lines (H9 and SA-01; white bars) and two HD-
derived NSC lines (Huez2.3, SIVF017; black bars): anterograde and retrograde velocities are higher in WT neurons than in HD cells. One-way ANOVAs
were conducted for anterograde and retrograde velocity separately. Anterograde: ***P,0.001; n = 43 to 170. Retrograde: **P,0.01; n = 43 to 133. (B)
Direct GFP and mCherry fluorescence and immunofluorescence staining of HTT in transfected neurons derived from one HD-hESC line (VUB05); these
cells were used for video-microscopy analyses. (C, D) Quantitative analyses of anterograde and retrograde BDNF vesicular velocities in SIVF017 cells
(C) and VUB05 cells (D) with representative kymographs and the analyzed trajectories (green for anterograde, red for retrograde and blue for pausing
vesicles). (C) One-way ANOVA for anterograde velocity: **P,0.01; n = 50 to 72. Fisher’s PLSD Post-hoc test demonstrated significant velocity recovery
with respect to the control group in the sh50T group, **P,0.01, but not in the sh50C group. For retrograde: F(2,198) = 3.095, *P,0.05; 55 to 77
events were recorded for each group. Fisher’s PLSD Post-hoc test demonstrated significant velocity recovery with respect to the control group in the
sh50T group, *P,0.05 but not in the si50C group. (D) One-way ANOVAs were conducted for anterograde and retrograde velocity separately. For
anterograde: F(2, 329) = 5.494, **P,0.01; 51 to 153 events were recorded for each group. Fisher’s PLSD Post-hoc test demonstrated a significant
increase in velocity for the sh50T group, **P,0.01 but not the sh50C group, with respect to the control group. For retrograde: F(2,313) = 2.585,
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and selectivity of the shSNPs targeting Exon50C/T and
Exon60G/A. The shSNPs specific for exon 39A/C and exon
67C/T were also extremely effective, although their discrimina-
tory power was not completely preserved. Additionally, besides a
strong transgene knockdown by targeting exon 39, as shown by
reduction of target RNA and ubiquitin inclusions, there was a
limited rescue of the lesion volume. These particular shRNAs
could be partially complementary to one or several rat’s transcripts
and lead to their expression alteration, ultimately causing toxicity.
Indeed, Jackson and collaborators [39] reported that 11 consec-
utive nucleotides could lead to unspecific degradation of off-target
mRNA. However, in a human context, the panel of potential
targets may be different because of sequence dissimilarities
between rodents and human, therefore the shSNP39 could be
better tolerated. Unfortunately, we are unable to verify this
hypothesis since none of our human neural stem cell lines are
heterozygous for SNP39; treating with either shSNP39 would
degrade the WT HTT allele, which would provoke transcriptomic
changes [6]. Work in Aronin’s lab suggests that placing the SNP
exon 39 at p16 of the shRNA might be more favorable than at p10
to discriminate the two alleles [13]. We tested this in vivo and found
no improvement in selectivity but, interestingly, the DARPP-32
lesion volume was significantly smaller indicating a better
tolerance of this sequence. These experiments demonstrate that
most of the shSNP can selectively reduce the expression of the
disease-causing HTT allele without significantly inhibiting expres-
sion of the WT allele in vitro or in vivo. To assess silencing of the
endogenous full-length HTT transcript, we injected the lentiviral
vectors into the striatum of BACHD mice. BACHD mice have
alleles which are present in most HD patients, whereas this is not
the case for YAC128 [15]. SNP in exons 39 and 50 are in linkage
disequilibrium with each other and with the CAG expansion, and
there are no such associations for the SNPs in exon 60 and 67 [14].
RT-qPCR analysis confirmed that all shRNAs targeting the SNPs
present in these animals led to efficient degradation of the full-
length mutant human HTT. It is important to mention that the
SNPs 67C/T were in their original context here (i.e. 39UTR)
whereas they were in the coding sequence in the lentiviral HD rat
model. Anyhow, it didn’t alter its ability to trigger RNA cleavage
as showed by decreased levels of HTT mRNA in both models.
Nevertheless, we can’t exclude that part of this effect is mediated
by translational repression or mRNA decay mediated by Ago1, 3
and 4 as previously demonstrated [40,41].
The clinical implementation of this type of strategy will require
the genotyping of HD patients for the selected SNPs, and, to treat
a large proportion of HD patients, the development of eight
therapeutic products (shSNP). A growing number of pre-clinical
and clinical trials have been launched to assess the use of RNAi for
the treatment of autosomal dominant diseases [42]. Both
exogenous oligonucleotides and shRNA produced by the target
cells are being investigated. Chemically modified siRNAs and
ASO have an excellent safety profile and half-life, but the issues of
crossing the blood-brain barrier to reach target cells in deep brain
areas and long-term administration in general still represent major
challenges for these therapeutic agents. Intraventricular infusion
allows broad diffusion throughout the brain, but the dose of
oligonucleotides needed to achieve efficient silencing are very high
and could lead to an oversaturation of the RNAi machinery at the
level of the RISC complex [9,43]. An alternative route of entry
into the CNS is intraparenchymal administration of appropriate
viral vectors. The design, production, and efficiency of gene
transfer vectors, especially for transduction of the central nervous
system (CNS), has improved remarkably, and protocols for safe
transduction and long-term and robust transgene expression in the
brain are now available [21,44-46]. These developments have led
to the initiation of several phase I/II clinical trials with adeno-
associated vectors (AAV) [47]; more recently trials have started
with lentiviral vectors for the treatment of adrenoleukodystrophy
[48] and Parkinson’s disease [49]. The issue of the safety of
shRNA (off target effects) and lentiviral vectors (genotoxicity
profile) needs further evaluation. Nevertheless, our study and the
rapidly accumulating data evidencing the potential value of this
type of approach argue for continued efforts to develop clinical
applications of these techniques.
Supporting Information
Figure S1 Correlation between HTT mRNA and protein
levels in 293T transfected cells. (A) Levels of the chimeric
HTT, represented by HA (representative pictures Figure 2B), were
normalized to tubulin and are reported as mean percentages
relative to the control condition (set at 100%) 6 SEM (n= 3).
One-way analyses of variance (ANOVA) were performed for each
SNP. Newman-Keuls Post-hoc comparison was conducted
between the control shRNA and matched shRNA (***p,0.001:
39A, 50C, 60A, 60G, 67C, 67T; **p,0.01: 50T) and between the
matched shRNA and mismatched shRNA (***p,0.001: 39A,
60A, 67C, 67T; **p,0.05: 60G). (B, C) Distribution of HTT RT-
qPCR and western blot data (n = 3) normalized on shUNIV results
in 293T cells obtained with all match (B) or mismatch (C)
shRNAs. Results demonstrate a high correlation between the HTT
mRNA and proteins quantities independently of the exon targeted
(for match shRNA: r = 0.63, p,0.01; for mismatch shRNAs:
r = 0.66, p,0.001).
(TIF)
Figure S2 Number of Ubiquitin-positive aggregates is
highly correlated to the number of HTT aggregates. (A)
and (B) EM-48 immunostaining and quantification showing large
numbers of aggregates in the control and mismatched injected
areas and fewer aggregates in the matched conditions for the SNP
50C and 50T (same animals as in Fig. 4). The results are
expressed as mean numbers of EM-48-positive aggregates 6 SEM
(n= 6–7). One-way ANOVAs were conducted for each SNP; 50C
and 50T: ***P,0.001. Newman-Keuls Post-hoc comparison
between control and matched conditions showed highly significant
prevention of aggregates formation for the matched shSNPs. For
mismatched conditions, the post-hoc test was not significant
compared to control condition. Matched and mismatched
conditions were significantly different for the 2 SNP studied
(50C: ***p,0.001; 50T: **p,0.01). (C) Correlation between the
numbers of Ubiquitin- and EM-48-positive aggregates quantified
from the same animals. EM-48-positive aggregates are always
more numerous but the number is highly correlated to the number
of ubiquitin-positive aggregates (Bravais-Pearson correlation
coefficient r = 0.93; p,0.001).
(TIF)
Figure S3 Efficacy and selectivity of the sh39A and
sh39C with SNP in p10 or p16. (A) Quantitative real-time
PCR analyses showing the silencing of HTT mRNA in transfected
P= 0.077; 44 to 144 events were recorded for each group. There was no significant difference between control group and treated groups for
retrograde transport.
doi:10.1371/journal.pone.0099341.g007
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293T cells co-expressing chimeric HTT and shSNP or the control
shRNA. Levels of the chimeric HTT mRNA were normalized to a
reference peptidyl propyl isomerase A (PPIA) and are expressed as
mean percentages relative to the control condition (set at 100%) 6
SEM (n=3). One-way ANOVAs were performed for each SNP.
Newman-Keuls Post-hoc comparison between the shCtrl and
shSNP groups indicated significant efficacy for the two SNP in the
two positions: sh39Ap10, sh39Ap16 (*P,0.05), sh39Cp10 and
sh39Cp16 (**P,0.01). The mismatched sh39p16 conditions were
significantly different from the control condition (sh39Ap16 (*P,
0.05) and sh39Cp16 (**P,0.01)). (B) and (C) Eight weeks post-
injection, DARPP32 and ubiquitin immunoreactivity were used to
quantify the lesion volume and the number of ubiquitin-positive
aggregates after sh39p10 or sh39p16 co-injection with htt171-82-
exon39. The results are expressed as means 6 SEM (n=8). One-
way ANOVAs were conducted for each SNP (**P,0.01; ***P,
0.001). Newman-Keuls post-hoc comparison between control and
matched shRNA groups concerning the size of the lesion showed
significant efficacy for the shSNP only in position 16 (B).
Regarding the number of aggregates (C), the four constructs were
effective. However, for the mismatched conditions, the post-hoc
test also revealed significant differences for both stainings revealing
that these shSNP are not selective.
(TIF)
Table S1 Sequences of the primers used to generate
fragments of HTT gene containing each SNP. The
sequences targeted by the shSNPs are in bold. The position of
the SNP is in red.
(DOC)
Table S2 Sequences of the oligonucleotides used to
generate the shRNA targeting the SNP and the controls.
The sense and anti-sense strands of the shRNA are given in bold.
The position of the SNP is in red.
(DOC)
Table S3 Sequences of the primers used for RT-qPCR.
(DOC)
Table S4 List of primer sequences used for SNP
sequencing in NSC.
(DOC)
Materials and Methods S1
(DOCX)
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